ClinicalTrials.gg
RecruitingNCT07389733Updated Apr 3, 2026

A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer

A Phase 1/2 interventional study of HRS-6208 Capsule and HRS-6209 Capsule in Advanced Unresectable or Metastatic Breast Cancer of Adults, sponsored by Shandong Suncadia Medicine Co., Ltd.. Recruiting at 2 sites in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-03.

Sponsored by Shandong Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
180
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing HRS-8080 in Breast Neoplasms — 8 open to participants now, 8 under way, 3 of them phase 3. HRS-8080 · Breast Neoplasms.

Planned enrollment
6th of 11
180 · median 180
Started
2026
with 4 others
Phase 1/2
4 of 11
4 open now
Registered
10th of 11
by date
Lead sponsor
11 of 11
Shandong Suncadia Medicine Co., Ltd.

Among the 11 studies testing HRS-8080 in Breast Neoplasms, this one is the 6th largest by planned enrollment, is one of 5 that started in 2026, is one of 4 in phase 1/2, and was the 10th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

8 of the 11 studies testing HRS-8080 in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

About HRS-8080

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing HRS-8080 in Breast Neoplasms, or all of them as a file.
02

Study summary

This study aims to evaluate the safety, tolerability, efficacy and pharmacokinetics of HRS-6208 in combination with HRS-8080 ± HRS-6209, or in combination with fulvestrant ± HRS-6209, or in combination with letrozole ± HRS-6209 in patients with advanced unresectable or metastatic breast cancer.

03

Conditions studied

  • Advanced Unresectable or Metastatic Breast Cancer of Adults

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female, aged 18-75 (inclusive);
  2. score 0-1;
  3. Estimated survival time ≥ 12 weeks;
  4. Possessing adequate bone marrow and organ function;
  5. Participants of reproductive/ must agree to take adequate and effective measures from the time they sign the form, during the study treatment period, and up to 2 years after the last use of the trial medication;
  6. Participants must provide informed consent for this study before the trial and voluntarily sign a written informed consent form.

Exclusion criteria

Exclusion Criteria:

  1. Within 5 years prior to the first dose of study medication, the occurrence of other , except for fully treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, and post-radical surgery thyroid papillary carcinoma;
  2. Active , carcinomatous meningitis, spinal cord compression, or history of primary central nervous system tumors;
  3. Severe bone damage caused by tumor bone as determined by the investigator;
  4. Adverse events caused by previous anti-tumor treatment have not been resolved;
  5. Participants with one of multiple factors affecting oral medication;
  6. History of severe cardiovascular and cerebrovascular diseases;
  7. Presence of severe infections;
  8. Significant bleeding within 3 months prior to the first dose of study medication;
  9. Active diseases, history of immune deficiency, history of autoimmune diseases, or history of diseases or syndromes requiring systemic hormone or drug treatment, or acquired conditions ( infection), congenital immune deficiency diseases, or history of organ transplantation;
  10. Active untreated hepatitis;
  11. History of active tuberculosis infection within 1 year prior to enrollment, or history of active tuberculosis infection more than 1 year ago without standard treatment;
  12. of prior drug or treatment did not meet protocol requirements before the first dose of study medication;
  13. Prior use of prohibited drugs specified in the protocol;
  14. Is pregnant or breastfeeding or planning to become pregnant within 2 years after the last dose of study medication;
  15. History of clear neurological or psychiatric disorders, and participants with a history of psychiatric drug abuse or drug addiction;
  16. Allergic reactions to any study drug or ;
  17. Factors confirmed by the investigator as unsuitable for participation in this clinical study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Arm A: HRS-6208 + HRS-8080 ± HRS-6209

    HRS-6208 + HRS-8080 ± HRS-6209.

    Drug: HRS-6208 Capsule · Drug: HRS-6209 Capsule · Drug: HRS-8080 Tablet

  • Experimental
    Arm B: HRS-6208 + Fulvestrant ± HRS-6209

    HRS-6208 + Fulvestrant ± HRS-6209.

    Drug: HRS-6208 Capsule · Drug: HRS-6209 Capsule · Drug: Fulvestrant injection

  • Experimental
    Arm C: HRS-6208 + Letrozole ± HRS-6209

    HRS-6208 + Letrozole ± HRS-6209.

    Drug: HRS-6208 Capsule · Drug: HRS-6209 Capsule · Drug: Letrozole tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicity (DLT)

    Time frame: The DLT will be evaluated for the last participant in each dose group 28 days after the first dose.

  2. Recommended phase II dose (RP2D)

    Time frame: The evaluation of RP2D will be completed approximately one year later than DLT evaluation.

  3. Incidence and severity of adverse events (AEs)

    Time frame: Each individual participant will be followed for approximately 8 months, and the entire study process will last for approximately 36 months.

  4. Objective response rate (ORR)

    Time frame: For a single subject, the duration will be approximately 8 months, while the entire research process will last for 36 months.

Secondary outcomes

  1. Disease control rate (DCR)

    Time frame: The duration for a single subject will be approximately 8 months, and the entire research process will last for 36 months.

  2. Duration of response (DoR)

    Time frame: The duration for a single subject will be approximately 8 months, and the entire research process will last for 36 months.

  3. Progression-free survival (PFS)

    Time frame: The duration for a single subject will be approximately 8 months, and the entire research process will last for 36 months.

  4. Overall survival (OS)

    Time frame: The duration for a single subject will be approximately 8 months, and the entire research process will last for 36 months.

  5. The blood drug concentration of HRS-6208

    Time frame: The duration for a single subject will be approximately 8 months, and the entire research process will last for 36 months.

  6. The blood drug concentration of HRS-8080

    Time frame: The duration for a single subject will be approximately 8 months, and the entire research process will last for 36 months.

  7. The blood drug concentration of HRS-6209

    Time frame: The duration for a single subject will be approximately 8 months, and the entire research process will last for 36 months.

  8. The blood drug concentration of Letrozole

    Time frame: The duration for a single subject will be approximately 8 months, and the entire research process will last for 36 months.

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2028, 33 months after the start.

Of 161 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's planned 33 months is below that.

Counting every sponsor, half of 328 studies reached it within 61 months; a quarter within 45 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2026
First posted
Feb 5, 2026
StartActual
Mar 27, 2026
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2028
Last update
Apr 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07389733
Responsible party
Sponsor
First posted
Feb 5, 2026
Start date
Mar 27, 2026
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Apr 3, 2026

Study contacts

Yunxia Feng
Contact
yunxia.feng.yf29@hengrui.com
+86-0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-8080

Start the discussion